Glioblastoma is a aggressive brain tumor known for its rapid growth and resistance to conventional treatments. Investigations are constantly underway to identify new therapeutic strategies, and recently, a new biomarker named LCA168 has emerged as a potential avenue for GBM treatment. LCA168 is a protein that is abundantly produced in glioblastoma